<DOC>
	<DOCNO>NCT01083758</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy daily use LEO 80185 topical suspension adolescent subject ( age 12 17 year ) scalp psoriasis . LEO 80185 topical suspension marketing approval many country brand name Taclonex Scalp® Topical Suspension Xamiol® gel treatment scalp psoriasis adult . No study perform subject young 18 year .</brief_summary>
	<brief_title>Safety Efficacy LEO 80185 Topical Suspension Adolescent Subjects ( Aged 12 17 ) With Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent give parent ( ) legal guardian follow receipt verbal write information study Subjects receive verbal write information provide write assent study Any race ethnicity Clinical sign psoriasis vulgaris trunk and/or limb , early diagnose psoriasis vulgaris trunk and/or limb At Screening Visit 2 Visit 1 clinical diagnosis scalp psoriasis : amenable topical treatment maximum 60 g study medication per week , extent equal 20 % scalp area least moderate severity accord investigator 's global assessment Subjects normal HPA axis function SV2 include serum cortisol concentration 5 mcg/dl ACTH challenge serum cortisol concentration 18 mcg/dl 30 minute ACTH challenge A serum albumincorrected calcium upper reference limit Screening Visit 2 Females childbearing potential must negative urine pregnancy test result must agree use highly effective method contraception ( abstinence acceptable method ) . Exclusion Criteria ( summary ) : A history serious allergy , allergic asthma serious allergic skin rash Known suspect hypersensitivity medication ( include ACTH/cosyntropin/tetracosactide ) component LEO 80185 topical suspension CORTROSYN Systemic treatment corticosteroid ( include inhale nasal steroid ) within 12 week prior Screening Visit 2 study Topical treatment corticosteroid within 2 week prior Screening Visit 2 study Oestrogen therapy ( include contraceptive ) medication know affect cortisol level HPA axis integrity within 4 week prior Screening Visit 2 study Enzymatic inductor ( e.g. , barbiturate , phenytoin , rifampicin ) cytochrome P450 inhibitor ( e.g. , ketoconazole , itraconazole , metronidazole ) within 4 week prior Screening Visit 2 study . Topical ketoconazole 2 week prior Screening Visit 2 Hypoglycemic sulfonamide Antidepressive medication within 4 week prior Screening Visit 2 study Known suspect endocrine disorder may affect result ACTH challenge test Systemic treatment biological therapy ( market market ) , possible effect scalp psoriasis within follow time period prior Visit 1 study within 4 weeks/5 halflives ( whichever longer ) prior Visit 1 Systemic treatment therapy biologicals , possible effect scalp psoriasis ( e.g. , retinoids , immunosuppressant , PUVA ) within 4 week prior Visit 1 ( Day 0 ) study Planned initiation , change , concomitant medication could affect scalp psoriasis ( e.g. , betablockers , chloroquine , lithium , ACE inhibitor ) study Other inflammatory skin disease may confound evaluation scalp psoriasis Known suspect disorder calcium metabolism associate hypercalcaemia</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>